(Reuters) - WASHINGTON, May 21 - U.S. regulators are
reviewing the safety of GlaxoSmithKline's Plc's diabetes drug
Avandia but have not yet determined the significance of risks
reported in a study released on Monday, a U.S. Food and Drug
Administration official said.
A study published in the New England Journal of Medicine
said Avandia increased the risk of cardiac-related deaths by 64
percent and heart attacks by 43 percent. Dr. Robert Meyer, head
of the FDA office that reviews diabetes drugs, said other data
contradicted those findings.
Read more at Reuters.com Government Filings News
reviewing the safety of GlaxoSmithKline's Plc's diabetes drug
Avandia but have not yet determined the significance of risks
reported in a study released on Monday, a U.S. Food and Drug
Administration official said.
A study published in the New England Journal of Medicine
said Avandia increased the risk of cardiac-related deaths by 64
percent and heart attacks by 43 percent. Dr. Robert Meyer, head
of the FDA office that reviews diabetes drugs, said other data
contradicted those findings.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment